About 60% of participants in a study of young adults infected with COVID-19 on a U.S. aircraft carrier had reactive antibodies to the virus, 59% of whom also had neutralizing antibodies at the time of specimen collection, according to a report released yesterday by the Centers for Disease Control and Prevention.

“The presence of neutralizing antibodies, which represent antibodies that inhibit SARS-CoV-2, among the majority (59.2%) of those with antibody responses is a promising indicator of at least short-term immunity,” the authors said.

Information about COVID-19 among young adults has been limited. One-fifth of the 382 study participants reported no symptoms, suggesting that symptom-based surveillance might not detect all infections. Participants who reported taking preventive measures, such as using face coverings and observing social distancing, had a lower infection rate than those who did not, reinforcing the importance of preventive measures to lower infection risk in congregate settings, the authors said.

Related News Articles

Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…